Protirelin tartrate (TRH-T) in upper motoneuron syndrome: a controlled neurophysiological and clinical study

What Was Tested

The paper reports a study of TRH (Thyrotropin-Releasing Hormone), published as a randomized controlled trial.

This randomised, single-blind, placebo-controlled study involved 20 patients with chronic upper motoneuron syndrome due to ischemic cerebrovascular lesions, selected in order to ensure the greatest possible homogeneity in terms of the severity of the syndrome.

The study included semiquantitative clinical evaluations of neurological examinations, with particular attention being paid to weakness and spasticity.

Who Took Part

According to the abstract, 20 patients were involved.

The age groups tagged for this paper are middle-aged adults and older adults.

How the Study Was Run

The researchers set it up as a randomized, single-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got TRH (Thyrotropin-Releasing Hormone) and who got the comparison, which limits bias.

In this single-blind TRH (Thyrotropin-Releasing Hormone) study one party knew the assignments and the other did not.

The comparison arm used a placebo, so changes seen with TRH (Thyrotropin-Releasing Hormone) could be set against what happens without it.

In the crossover set-up each of the patients took both TRH (Thyrotropin-Releasing Hormone) and the comparison in turn, acting as their own control.

What Was Measured

This randomised, single-blind, placebo-controlled study involved 20 patients with chronic upper motoneuron syndrome due to ischemic cerebrovascular lesions, selected in order to ensure the greatest possible homogeneity in terms of the severity of the syndrome.

The study included semiquantitative clinical evaluations of neurological examinations, with particular attention being paid to weakness and spasticity.

PubMed files the paper under topics including Cerebral Infarction, Electrophysiology, Evoked Potentials, Motor Neuron Disease, Motor Neurons, Muscle Spasticity and Thyrotropin-Releasing Hormone.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of TRH (Thyrotropin-Releasing Hormone) in 20 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1994 (Italian journal of neurological sciences), a journal based in Italy.

More context: the TRH (Thyrotropin-Releasing Hormone) compound page, all human trials.